Form 4: Alexander Denner Reports Acquisition of Ironwood Pharmaceuticals Shares and Indirect Ownership Through Sarissa Capital

Alexander Denner, a director and 10% owner of Ironwood Pharmaceuticals, reported acquiring shares and indirect beneficial ownership through Sarissa Capital Management.

Summary

• Alexander Denner, a director and 10% owner of Ironwood Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On September 16, 2024, Denner acquired 3,282 shares of Class A Common Stock at $0 per share, pursuant to the Second Amended and Restated Non-employee Director Compensation Policy.
• Denner also indirectly beneficially owns 16,390,000 shares through Sarissa Capital Management LP and its associated funds.
• Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
• Sarissa Capital Management LP, as investment advisor to the Sarissa Funds, also reported indirect beneficial ownership of the shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing changes in beneficial ownership. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of shares by a director may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates changes in Alexander Denner's ownership stake in Ironwood Pharmaceuticals.

Stakeholder Impact

• Shareholders are informed about changes in ownership by a significant shareholder and director.

Key Dates